No Data
No Data
Satellos to Present Data on SAT-3247 Pilot Study at World Muscle Society Meeting
Satellos Bioscience Inc. Initiated at Speculative Buy by Canaccord Genuity
Satellos Announces Dosing of First Participant in Phase 1 Clinical Study of SAT-3247
Satellos Announces Participation in September 2024 Investor Conferences
Satellos Bioscience Given Go-ahead for Phase 1 Clinical Trial With SAT-3247 in Australia
Satellos Bioscience Brief: Adds "On Track: to Dose First Participant in Phase 1 Clinical Trial With SAT-3247 in Q3 2024; Cites Cash Balance of $27.7 Million at June 30, 2024
No Data